Brief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
07/10/2026 13:22
BRIEF-FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition Oct 7 (Reuters) - SeaStar Medical Holding Corp ICU.O:
FDA GRANTS SEASTAR MEDICAL BREAKTHROUGH DEVICE DESIGNATION FOR ITS SCD THERAPY FOR THE TREATMENT OF HYPERINFLAMMATION IN ADULT PATIENTS WITH SEPSIS OR A SEPTIC CONDITION
Source text: ID:nGNX2xB1yB
Further company coverage: ICU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview